News

Medscape20d
FDA OKs Cabozantinib for Pancreatic Neuroendocrine Tumors
The US Food and Drug Administration (FDA) has approved cabozantinib (Cabometyx, Exelixis, Inc.) for certain adults and children aged ≥ 12 years with previously treated, well-differentiated ...
The Victoria Advocate16d
FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine Tumors
MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration has approved cabozantinib (Cabometyx), an oral tyrosine kinase inhibitor, for patients with previously treated ...
Morningstar20d
Exelixis Announces U.S. FDA Approval of CABOMETYX® (cabozantinib) for Patients with Previously Treated Advanced Neuroendocrine Tumors
“It was encouraging to see that cabozantinib resulted in significant delays in disease progression in the CABINET trial—regardless of primary tumor site and grade. This FDA approval marks a ...
KHQ16d
FDA Approves Cabozantinib for Previously Treated Advanced Neuroendocrine Tumors
From breaking news to special features, we're on it! Join the NonStop Local Chord group and always be in the know. MONDAY, March 31, 2025 (HealthDay News) -- The U.S. Food and Drug Administration ...